ICML 2023 | Exploring the impact of magnesium levels on the outcomes of patients with LBCL receiving axi-cel
Patrizia Mondello, MD, PhD, Mayo Clinic, Rochester, MN, discusses a study in which single-cell analysis was used to investigate the impact of magnesium levels on the outcomes of patients with large B-cell lymphoma (LBCL) receiving treatment with axicabtagene ciloleucel (axi-cel). Results demonstrated that patients with hypomagnesemia were associated with an inferior progression-free and overall survival (PFS; OS), highlighting the important role of magnesium in patient response to CAR-T therapy. Furthermore, magnesium levels had an impact on levels of inflammatory cytokines, suggesting an immune modulatory effect. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
